DK1220685T3 - Farmaceutiske præparater af fibrinolytisk middel - Google Patents

Farmaceutiske præparater af fibrinolytisk middel

Info

Publication number
DK1220685T3
DK1220685T3 DK00967197T DK00967197T DK1220685T3 DK 1220685 T3 DK1220685 T3 DK 1220685T3 DK 00967197 T DK00967197 T DK 00967197T DK 00967197 T DK00967197 T DK 00967197T DK 1220685 T3 DK1220685 T3 DK 1220685T3
Authority
DK
Denmark
Prior art keywords
fibrinolytic agent
pharmaceutical preparations
lyophilized
agent
lyophilized composition
Prior art date
Application number
DK00967197T
Other languages
English (en)
Inventor
Brian Peterson
Brent S Kendrick
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1220685T3 publication Critical patent/DK1220685T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00967197T 1999-10-01 2000-09-29 Farmaceutiske præparater af fibrinolytisk middel DK1220685T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/411,335 US6440414B1 (en) 1999-10-01 1999-10-01 Pharmaceutical compositions of fibrinolytic agent

Publications (1)

Publication Number Publication Date
DK1220685T3 true DK1220685T3 (da) 2004-08-02

Family

ID=23628514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00967197T DK1220685T3 (da) 1999-10-01 2000-09-29 Farmaceutiske præparater af fibrinolytisk middel

Country Status (28)

Country Link
US (4) US6440414B1 (da)
EP (2) EP1220685B1 (da)
JP (1) JP2003510369A (da)
KR (1) KR100717435B1 (da)
CN (2) CN101209347A (da)
AT (1) ATE262923T1 (da)
AU (1) AU769313B2 (da)
BG (1) BG106578A (da)
BR (1) BR0014420A (da)
CA (1) CA2385966A1 (da)
CZ (1) CZ20021033A3 (da)
DE (2) DE04007657T1 (da)
DK (1) DK1220685T3 (da)
EA (2) EA004627B1 (da)
ES (2) ES2224917T1 (da)
HK (1) HK1049112B (da)
HU (1) HUP0202654A3 (da)
IL (1) IL148842A0 (da)
MX (1) MXPA02003197A (da)
NO (1) NO20021500L (da)
NZ (4) NZ540967A (da)
PL (1) PL355016A1 (da)
PT (1) PT1220685E (da)
SG (1) SG148823A1 (da)
SK (1) SK4242002A3 (da)
WO (1) WO2001024817A2 (da)
YU (1) YU23302A (da)
ZA (1) ZA200202400B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US7033776B2 (en) * 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
EP1469886B8 (en) * 2002-02-01 2008-01-09 Shimoda Biotech (PTY) LTD Lyophilized pharmaceutical composition of propofol
EP1476178A4 (en) * 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp FORMULATION STRATEGIES IN STABILIZING PEPTIDES IN ORGANIC SOLVENTS AND DRY CONDITIONS
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
CA2589889C (en) * 2004-12-15 2013-07-30 Amgen Inc. Therapeutic formulations of keratinocyte growth factor
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2008056840A1 (en) * 2006-11-08 2008-05-15 Silla University Industry Academic Cooperation Foundation Fibrinolytic metalloprotease and composition comprising the same
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
EP2451835A1 (en) 2009-07-10 2012-05-16 ThromboGenics N.V. Variants of plasminogen and plasmin
CN102000022A (zh) * 2010-11-23 2011-04-06 郑州大学 注射用重组双功能纤溶酶冻干制剂及其制备方法
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US20140212405A1 (en) 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
EP3215634B1 (en) * 2014-11-06 2021-08-04 The Regents of the University of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
CN113382714A (zh) * 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
JPS57500844A (da) * 1980-06-27 1982-05-13
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US4848700A (en) * 1987-04-16 1989-07-18 Lockheed John A Canard control system for aircraft
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
DK0438200T3 (da) 1990-01-16 2002-11-11 Ct Ingenieria Genetica Biotech Fremgangsmåde til ekspression af heterologe gener i gæren Pichia pastoris, ekspressionsvektorer og transformerede mikroorganismer
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
ATE249234T1 (de) 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
AU2001281081A1 (en) 2000-08-03 2002-02-18 Zymogenetics Inc. Disintegrin homologs, zsnk10, zsnk11, and zsnk12

Also Published As

Publication number Publication date
AU769313B2 (en) 2004-01-22
DE60009529D1 (de) 2004-05-06
NZ518007A (en) 2004-03-26
ATE262923T1 (de) 2004-04-15
KR100717435B1 (ko) 2007-05-14
ES2224917T1 (es) 2005-03-16
ZA200202400B (en) 2003-05-28
JP2003510369A (ja) 2003-03-18
PT1220685E (pt) 2004-08-31
HUP0202654A2 (hu) 2002-12-28
EP1438967A2 (en) 2004-07-21
SG148823A1 (en) 2009-01-29
NZ530959A (en) 2005-08-26
EP1220685B1 (en) 2004-03-31
NZ540967A (en) 2007-02-23
US20060263347A1 (en) 2006-11-23
EA004627B1 (ru) 2004-06-24
CN100353999C (zh) 2007-12-12
HUP0202654A3 (en) 2003-11-28
HK1049112B (en) 2005-01-21
BG106578A (bg) 2003-04-30
SK4242002A3 (en) 2003-08-05
CA2385966A1 (en) 2001-04-12
EP1438967A3 (en) 2005-01-26
ES2218228T3 (es) 2004-11-16
YU23302A (sh) 2005-06-10
NO20021500L (no) 2002-05-27
WO2001024817A2 (en) 2001-04-12
DE04007657T1 (de) 2005-01-13
BR0014420A (pt) 2002-06-11
CN101209347A (zh) 2008-07-02
CN1402641A (zh) 2003-03-12
IL148842A0 (en) 2002-09-12
US20020192207A1 (en) 2002-12-19
US6440414B1 (en) 2002-08-27
US7138114B2 (en) 2006-11-21
MXPA02003197A (es) 2002-09-30
US7311908B2 (en) 2007-12-25
KR20020053065A (ko) 2002-07-04
PL355016A1 (en) 2004-03-22
CZ20021033A3 (cs) 2003-06-18
EA200400182A1 (ru) 2004-08-26
WO2001024817A3 (en) 2001-10-18
AU7743000A (en) 2001-05-10
DE60009529T2 (de) 2005-04-14
US20060246053A1 (en) 2006-11-02
EP1220685A2 (en) 2002-07-10
HK1049112A1 (en) 2003-05-02
EA200200396A1 (ru) 2002-10-31
NZ550200A (en) 2008-04-30
US7244426B2 (en) 2007-07-17
EA006600B1 (ru) 2006-02-24
NO20021500D0 (no) 2002-03-26

Similar Documents

Publication Publication Date Title
NO20021500D0 (no) Farmasöytiske preparater av fibrinolytisk middel
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
FR2774909B1 (fr) Formulation pharmaceutique, solution de perfusion et composition lyophilisee comprenant une epothilone.
MY133996A (en) Compounds for the treatment of ischemia
PT762896E (pt) Composicoes de tocoferol para administracao de agentes biologicamente activos
DK0915898T3 (da) Krystalform I af clarithromycin
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
PT1083884E (pt) Processo para a estabilizacao de composicoes de polivinil-pirrolidona
BR9712544B1 (pt) Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
AU1081901A (en) Improved rotary shaft bearing isolator seal
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
PT1054686E (pt) Formulacao farmaceutica de um composto de didemnina
EP1053010A4 (en) COPOLYMER COMPOSITIONS FOR ORAL ADMINISTRATION
NO944764D0 (no) Inklusjonskomplekser i vandige opplösninger av benzotiofenforbindelser med vannopplöselige cyklodekstriner og farmasöytiske formuleringer og fremgangsmåter
DK1213962T3 (da) Pesticidpræparater, der som overfladeaktive forbindelser indeholder phosphatestere og alkoxylerede ligninsulfonater
IL142720A0 (en) Water-miscible pharmaceutical compositions of paclitaxel
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
IT1287174B1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
PT1173194E (pt) Sp-a recombinante para o tratamento ou a prevencao da infeccao e da inflamacao pulmonares
AR026890A1 (es) Composiciones de tenocitos, preparaciones y utilizaciones
DK1800664T3 (da) Farmaceutiske formuleringer til parenteral indgivelse indeholdende epothilon